Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. - Wikidata - awgldk - TriplyDB

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

http://www.wikidata.org/entity/Q30376757

about

Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials Vaccinology in the third millennium: scientific and social challenges B Cells and Functional Antibody Responses to Combat Influenza H5N1 vaccines in humans Mucosal Immunosenescence in the Gastrointestinal Tract: A Mini-Review Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants A molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderly Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults.Investing in Immunity: Prepandemic Immunization to Combat Future Influenza Pandemics.Clinical vaccine development for H5N1 influenza.Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.Avian influenza A H5N1 virus: a continuous threat to humans.Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza.Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.Considerations for the rapid deployment of vaccines against H7N9 influenza.Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study.Effect of influenza A(H5N1) vaccine prepandemic priming on CD4+ T-cell responses.A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin Refining the approach to vaccines against influenza A viruses with pandemic potential.Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice.Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine.Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine.Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.H1N1: can a pandemic cycle be broken?MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets MF59 adjuvant: the best insurance against influenza strain diversity.Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.Seasoned adaptive antibody immunity for highly pathogenic pandemic influenza in humans.Pandemic influenza vaccines - the challenges.

P2860

Q21131308-4E7F5E0B-37A1-44EE-81FF-8AA98766F599 Q24261399-6306EBB9-F2DD-4509-8D23-87BAC95F5603 Q26801639-B5E85DC8-A481-48C0-905D-6F6CE6534F35 Q27000896-5497772F-8B9D-457C-8ED0-252565CF90EC Q27015768-6DBB4E5F-721C-4A19-82C3-0A3BD7346EB2 Q27304735-BABB02F9-58DB-412D-8B97-97FB12FCD2DE Q28084760-4290ECC6-A547-4466-BE3E-19D607CA1976 Q30151510-8D4848E3-7030-470D-9FFA-99D23DDE95AE Q30202032-B795A0F7-1341-4A21-80AC-62400C27F56B Q30222083-71C4C150-F60F-4330-BB22-7617E7A03CE5 Q30223941-0A3A67C4-28F9-459C-AEEF-4BF6C3D40334 Q30224462-DA06D150-30B3-45F4-B201-4D667669CC07 Q30227194-2689A098-BA5D-4BB9-B8E7-FC7C0679F713 Q30352329-328A5483-8F83-4BD0-861E-4778714A6733 Q30359243-DFF0A169-8EB9-46DE-8883-D36D19D03862 Q30361644-DB22AE8A-F534-4F95-9374-A2D9CFB11C81 Q30362811-CE46F9F6-F302-4768-AB4E-A9D8A130A03B Q30364635-430F80B6-89F0-4731-836D-8D5E3747CED9 Q30368239-98C9FC8A-4D1A-4241-8864-34BB8C351D0F Q30368474-71A55082-2A58-4772-BB83-5185EEF8097A Q30368934-DFB3C729-A60F-4E3A-8131-3DD891DA5E72 Q30371303-C53D4CDA-29E2-4431-B91D-232A1AFC9DCF Q30372087-C8F8842F-2079-42EB-B04D-56905C20E557 Q30380290-CC7BD6CB-67BE-4E82-B860-752D45977C69 Q30381595-ACFA03FE-6B42-4069-8D07-4298100E63E8 Q30383449-148F0554-43E7-4FE4-B68A-E0F6238AF68F Q30383451-D297625A-C530-4A0D-BDBD-B188C78E2F81 Q30383794-497270DB-C943-44F6-8836-F8BC20883CA4 Q30384943-C81DEB8F-1A16-4862-B1F1-91BED19DF332 Q30385138-E31C814C-20FE-4D96-AFF2-E8A00E740264 Q30387739-DABBE201-6A34-491B-9883-6E03DEB34DFE Q30387826-2F34AFCC-0D83-4B2A-B6AC-3B1E4C0492F7 Q30394545-16A0D094-6500-4EBE-BE03-7667B676EEA8 Q30394896-18C5556A-94E1-4205-BDAF-80EB7463E590 Q30398277-6FCBD9AA-DB50-47B0-BB70-BE297A1D0DD9 Q30402018-26F5552E-68FA-4A0F-8805-71AC786BA816 Q30402500-A93BD11B-E715-481A-860C-3521BE6CBF2E Q30403361-70A8D128-EB39-431C-80C3-AB2E43E35AE1 Q30403507-2C8243FC-7894-4245-911A-BB1EDBDF66FF Q30408091-24F4505C-58DD-4DC7-82BE-7E887DE79DEC

P2860

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

http://www.wikidata.org/entity/Q30376757

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Fast rise of broadly cross-rea ...... djuvanted prepandemic vaccine.

@ast

Fast rise of broadly cross-rea ...... djuvanted prepandemic vaccine.

@en

type

label

Fast rise of broadly cross-rea ...... djuvanted prepandemic vaccine.

@ast

Fast rise of broadly cross-rea ...... djuvanted prepandemic vaccine.

@en

prefLabel

Fast rise of broadly cross-rea ...... djuvanted prepandemic vaccine.

@ast

Fast rise of broadly cross-rea ...... djuvanted prepandemic vaccine.

@en

P1433

Q30376757-86228D3B-111B-46B7-A64D-FAD5BC36630A

P1476

Q30376757-78D8849B-D961-4CD3-B9BD-013C6B5AD37D

P2093

Q30376757-09CE1D35-7958-4FFA-8C8F-F0ABE38AC36B

Q30376757-0D37A0C0-5B31-4166-B3CF-670C329235A6

Q30376757-1E6E5BE9-9C5A-4C58-9184-92D8724ADD13

Q30376757-1FA3B28A-89A3-4FFF-ACB8-0023280FFF1C

Q30376757-5F21BD4A-841C-46B3-B4CF-6E6F3FFD35A2

Q30376757-788B7837-95E1-4CE2-9F47-DEEF4D86A74A

Q30376757-9D401C0B-2FC9-4638-9681-11E4B35BECA1

Q30376757-B0B814CF-FDC2-4941-8E2B-FBB90B1B467A

Q30376757-B0D2A8ED-3B58-40B2-8DD7-AE514E744114

Q30376757-B6E8E48C-7076-4B55-8BDC-E694115ED50D

P2860

Q30376757-076A8CD1-7FDD-494C-95EA-A8B0B8D0A0E0

Q30376757-1007DC3A-D818-4F3B-B846-B415761CE725

Q30376757-1C458555-C3B0-48F0-BBB4-521F4DF04818

Q30376757-2CBEE784-D26F-4955-A404-72A73EC9C9C1

Q30376757-3555AC9F-1E5C-4C4F-893A-81A0705A8DA5

Q30376757-3B4FBE11-B137-44E3-A696-51987586EFC8

Q30376757-63616754-8911-4086-89AF-F9F813177C45

Q30376757-6619BEA6-D812-4F21-B5F8-C0AD42862CBF

Q30376757-724CA66D-4FE4-470B-A472-058BFEE6D3A8

Q30376757-80535157-A190-42F7-A459-BDFA9000E306

P304

Q30376757-1B741F13-E194-4BB8-94F8-C54AE9F37422

P31

Q30376757-339D38E3-6C2E-411B-BB8B-7629EBFF92EE

P356

Q30376757-9FF7E2D2-64AC-4C65-A71A-CA30BFD1589C

P407

Q30376757-DD414FC3-6A89-4129-AC62-F23063F44392

P433

Q30376757-1AF073B7-C084-465D-B231-E4ACBE346536

P478

Q30376757-71396A71-6288-48D9-8FC4-81D8F4CC8B0D

P50

Q30376757-21C33E45-935C-489B-8FB4-89599DD2EEC4

Q30376757-78F82054-6FFD-4DF2-B5F2-5500881C1713

Q30376757-EA90A21D-F9A7-4D74-982C-0A2655C96229

P577

Q30376757-3E184BE9-59D1-4CD7-B405-7CB246C411AB

P5875

Q30376757-C2EEBD7C-DB9E-4466-8E38-8FE1D053C00D

P698

Q30376757-4FAF92D3-812F-4F47-97B3-E3118FA28ABA

P921

Q30376757-205139C9-2035-435F-8FBA-270181EF6564

P932

Q30376757-A5CEBADE-4ED3-4BD7-B5BD-C955E10E34F1

P356

PNAS.0903181106

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Fast rise of broadly cross-rea ...... djuvanted prepandemic vaccine.

@en

P2093

Angelika Banzhoff

http://www.w3.org/2001/XMLSchema#string

Carmine Malzone

http://www.w3.org/2001/XMLSchema#string

Chiara Gentile

http://www.w3.org/2001/XMLSchema#string

Flora Castellino

http://www.w3.org/2001/XMLSchema#string

Giuseppe Del Giudice

http://www.w3.org/2001/XMLSchema#string

Grazia Galli

http://www.w3.org/2001/XMLSchema#string

Iain Stephenson

http://www.w3.org/2001/XMLSchema#string

Joshua DeVos

http://www.w3.org/2001/XMLSchema#string

Karl Nicholson

http://www.w3.org/2001/XMLSchema#string

Kathy Hancock

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans

Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control

Strategies for mitigating an influenza pandemic

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

P304

7962-7967

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0903181106

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Emanuele Montomoli

Jacqueline M. Katz

P577

2009-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24403050

http://www.w3.org/2001/XMLSchema#string

P698

19416838

http://www.w3.org/2001/XMLSchema#string

P921

P932

2674105

http://www.w3.org/2001/XMLSchema#string